Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Abstract
AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen receptor–positive breast cancer in combination with fulvestrant. Here, we aimed to identify response biomarkers and uncover mechanisms of resistance to AZD5363 and its combination with paclitaxel.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 15, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3324
Entities
People
- Alan Barnicle
- Albert Gris-Oliver
- Aleix Prat
- Alejandra Bruna
- Andreu Òdena
- Avinash Reddy
- Barry R. Davies
- Carlos Caldas
- Caroline S. Hirst
- Cristina Saura
- Elza C. De Bruin
- Fara Brasó-maristany
- Gaia Schiavon
- Gordon B. Mills
- Guillermo Villacampa
- Joaquin Arribas
- Judit Grueso
- Laia Monserrat
- Mafalda Oliveira
- Marta Guzmán
- Marta Palafox
- Maurizio Scaltriti
- Mireia Parés
- Mònica Sánchez-guixé
- Nicholas C. Turner
- Olga Rodríguez
- Paolo Nuciforo
- Pedram Razavi
- Rodrigo Dienstmann
- Violeta Serra
- Yasir H. Ibrahim
Organizations
- Agency for Administration of University and Research
- AstraZeneca
- Autonomous University of Barcelona
- Carlos III Health Institute
- Congressionally Directed Medical Research Programs
- Hospital Clinic of Barcelona
- Memorial Sloan Kettering Cancer Center
- Ministry of Economy, Industry and Competitiveness
- National Cancer Institute
- National Institutes of Health
- Oregon Health & Science University
- Royal Marsden Hospital
- Spanish Association Against Cancer
- University of Cambridge
- University of Texas at Austin
- Vall d'Hebron Institute of Oncology